WHO Raises Warning Over Critical Lack of Obesity Jabs

Fewer than 10% of patients eligible to benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it issues its inaugural guidance on the medications.

Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for more widespread and fairer availability to these injectable treatments.

Per estimates, over two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with comprehensive and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major hurdles to widespread access to the jabs that can help people shift substantial weight, notes the agency.

GLP-1 Therapy Supply Crisis

Despite the present best projected outlook, the production of such drugs could only cover about 100 million people – less than 10% of those who need them, according to the WHO.

The recommendation calls on countries and companies to increase access, via measures including patent sharing.

Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.

How Obesity Injections Operate

These medications replicate a biological compound to delay gastric emptying, suppress the appetite and boost feelings of fullness so individuals eat less.

Patients typically start to lose weight after several weeks of starting on the weekly injections.

Research indicates people may see weight return a year later of halting the medication, because their usual food cravings return.

To be above a healthy weight raises your likelihood for contracting diseases, including type 2 diabetes, heart disease, brain attack, and specific malignancies.

Obesity affects people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.